Thrombocytopenia: Optimizing approaches in cancer patients

Caroline Piatek, Mojtaba Akhtari

Research output: Contribution to journalArticlepeer-review

Abstract

Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of  hrombocytopenia in the cancer setting In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles In this issue of ONCOLOGY Dr Kuter insightfully summarizes the differential diagnosis and management of thrombocytopenia in cancer patients[1] Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of hrombocytopenia in the cancer setting[2] In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles

Original languageEnglish (US)
JournalOncology (United States)
Volume29
Issue number4
StatePublished - 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Thrombocytopenia: Optimizing approaches in cancer patients'. Together they form a unique fingerprint.

Cite this